Zhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF

Stock News

Dec 08, 2025

Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan. Tansheng Pharma specializes in chronic diseases and precision medicine, delivering safe and accessible healthcare solutions.

Under the agreement, Zhaoke grants Tansheng Pharma exclusive distribution rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan.

In June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1180947982"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180947982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180947982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 16:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180947982","market":"us","top_or_hot":-1,"title":"Zhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF","media":"Stock News","content":"<p>Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan. Tansheng Pharma specializes in chronic diseases and precision medicine, delivering safe and accessible healthcare solutions.</p>\n<p>Under the agreement, Zhaoke grants Tansheng Pharma exclusive distribution rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan.</p>\n<p>In June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 16:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan. Tansheng Pharma specializes in chronic diseases and precision medicine, delivering safe and accessible healthcare solutions.</p>\n<p>Under the agreement, Zhaoke grants Tansheng Pharma exclusive distribution rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan.</p>\n<p>In June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1180947982","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180947982","pubTimestamp":1765184087,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","BK1587":"次新股","BK1574":"生物医药B类股","06622":"兆科眼科-B","01477":"欧康维视生物-B"},"translate_title":"兆科眼科-B(06622)将与台湾丹生制药合作开展BRIMOCHOL的临床引进及未来商业化™PF","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"06622":1},"content_text":"Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan. Tansheng Pharma specializes in chronic diseases and precision medicine, delivering safe and accessible healthcare solutions.\nUnder the agreement, Zhaoke grants Tansheng Pharma exclusive distribution rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan.\nIn June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}